犬類特異性皮膚炎市場：市場機會、成長要素、產業趨勢分析及2026-2035年預測

2025 年全球犬類異位性皮膚炎市場價值為 15 億美元，預計到 2035 年將以 9.2% 的複合年成長率成長至 36 億美元。

犬異位性皮膚炎盛行率的上升以及人們對伴侶動物保健日益成長的關注，是推動該市場成長的主要因素。寵物飼主對寵物健康的日益重視，也帶動了對先進獸醫皮膚病治療的需求。此外，獸藥的創新也對市場產生了積極影響，因為寵物飼主和獸醫都在尋求安全、有效且針對性強的慢性皮膚病治療方法。已開發市場和新興市場獸醫基礎設施的不斷改進以及專科診所的增多，使得更多犬隻能夠得到正確的診斷和治療。新興市場居民可支配收入的增加，進一步促進了對寵物保健的投資。隨著人們對預防性和持續性皮膚護理重要性的認知不斷提高，犬特發性皮膚炎市場在各個地區都呈現出穩定且持續的成長態勢。

犬特異性皮膚炎是一種慢性發炎性皮膚病，與遺傳因素有關，由對蟎蟲、花粉、真菌或某些食物等環境過敏原的超敏反應引發。此病會引發過度免疫反應，導致持續性搔癢、發紅以及反覆發生的皮膚和耳部感染疾病。單株抗體和口服療法等創新獸藥治療方法的研發顯著改變了此疾病的治療管理。單株抗體可針對並緩解搔癢和炎症，而口服療法則具有長期治療的便利性和有效性。人們對伴侶動物健康（尤其是在新興經濟體）的認知不斷提高，這正在推動獸藥療法的應用和投資不斷成長。

預計到2025年，糖皮質激素類藥物市場規模將達5.116億美元。這些藥物，包括潑尼松和地塞米松，能迅速有效地緩解發炎和搔癢，因此是治療重症和急性發作的第一線藥物。與新型標靶治療相比，它們價格實惠，這促進了其持續普及，尤其是在獸醫資源匱乏、寵物保險覆蓋率低的地區。

預計到2025年，口服給藥途徑將佔47.3%的市佔率。奧克拉替尼和糖皮質激素等口服藥物因其使用方便性而受到寵物飼主的青睞，有助於提高用藥依從性並確保治療的持續性。這些治療方法能夠迅速緩解搔癢和炎症，對急性和慢性症狀均有效。標靶口服療法透過特異性調節發炎路徑來增強療效，因此在獸醫皮膚病學領域越來越受歡迎。

北美犬類異位性皮膚炎市場佔據41%的市場佔有率，預計到2035年將以9%的複合年成長率成長。該地區市場成長的主要促進因素包括：完善的獸醫基礎設施、創新皮膚病治療方案的普及以及單株抗體等先進治療方法的廣泛應用。寵物飼主日益成長的專業照護意願以及犬類慢性皮膚病的高發生率進一步鞏固了北美市場的領先地位。

目錄

第1章：調查方法

• 市場範圍和定義
• 研究途徑
• 對品質的承諾
  • GMI的AI政策與對資料完整性的承諾
    • 資訊來源一致性通訊協定
• 調查過程和可靠性評分
  • 研究路徑的組成部分
  • 評分組成部分
• 數據收集
  • 主要來源部分列表
• 資料探勘資訊來源
  • 付費資訊來源
    • 區域資訊來源
• 基本估算和計算方法
  • 收入佔有率分析
  • 基準年的計算
• 預測模型
• 關於調查透明度的補充信息
  • 資訊來源歸屬框架
  • 品質保證指標
  • 對信任的承諾

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 寵物數量的增加和寵物的人性化
    • 對皮膚疾病和先進治療方法方案的認知不斷提高
  • 產業潛在風險與挑戰
    • 某些藥物的副作用
    • 人用藥品的仿單標示外使用
  • 市場機遇
    • 聯合治療的需求和使用增加
    • 開發一種用於治療兒童潰瘍性大腸炎的藥物
• 成長潛力分析
• 監理情勢（基於初步調查）
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
• 價格分析（基於初步調查）
• 研發管線和臨床試驗趨勢
• 未來市場趨勢
• 人工智慧和生成式人工智慧對市場的影響
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 業務拓展計劃

第5章 市場估價與預測：依產品分類，2022-2035年

• 糖皮質激素
• 抗組織胺藥
• 免疫抑制劑
• 單株抗體
• 其他產品

第6章 市場估計與預測：依給藥途徑分類，2022-2035年

• 口服
• 外用
• 注射藥物

第7章 市場估價與預測：依通路分類，2022-2035年

• 零售藥房
• 獸藥
• 網路藥房

第8章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• AB Science
• Boehringer Ingelheim
• Ceva
• Dechra Veterinary Products
• Elanco
• Kindred Biosciences
• Nextmune（Vimian）
• Phibro Animal Health Corporation
• Toray Industries
• Vetoquinol
• Virbac
• Zoetis

The Global Canine Atopic Dermatitis Market was valued at USD 1.5 billion in 2025 and is estimated to grow at a CAGR of 9.2% to reach USD 3.6 billion by 2035.

The market growth is driven by the rising prevalence of atopic dermatitis in dogs and a growing focus on companion animal healthcare. Increasing awareness among pet owners about their pets' well-being is fueling demand for advanced veterinary dermatology therapies. The market is also benefiting from innovations in veterinary medications, as pet owners and veterinarians seek safe, effective, and targeted treatment options for chronic skin conditions. With the expansion of veterinary infrastructure and specialized clinics in both developed and emerging regions, more dogs are receiving proper diagnosis and treatment. Rising disposable incomes in emerging markets further encourage investments in pet healthcare. As awareness of the importance of preventative and ongoing dermatological care spreads, the canine atopic dermatitis market is witnessing steady and sustained growth across geographies.

Canine atopic dermatitis is a chronic, genetically influenced inflammatory skin disorder caused by hypersensitivity to environmental allergens like dust mites, pollen, mold, or specific foods. The condition triggers an exaggerated immune response, resulting in persistent itching, redness, and recurrent skin and ear infections. The development of innovative veterinary treatments such as monoclonal antibodies and oral therapies has transformed disease management. Monoclonal antibodies offer targeted relief from pruritus and inflammation, while oral therapies provide convenience and efficacy for long-term treatment. Rising knowledge of companion animal health, especially in emerging economies, is driving higher adoption rates and increased investment in veterinary therapeutics.

The glucocorticoids segment generated USD 511.6 million in 2025. These medications, including prednisone and dexamethasone, are highly effective in rapidly alleviating inflammation and itching, making them the preferred choice for severe or acute flare-ups. Their affordability compared to newer targeted therapies supports their continued adoption, particularly in regions with limited access to advanced veterinary care or low pet insurance penetration.

The oral administration segment held a 47.3% share in 2025. Oral medications like oclacitinib and glucocorticoids are favored by pet owners due to ease of use, which improves compliance and ensures consistent treatment. These therapies deliver fast relief for pruritus and inflammation and are effective for both acute and chronic conditions. Targeted oral treatments enhance efficacy by specifically modulating inflammatory pathways, reinforcing their popularity in veterinary dermatology practices.

North America Canine Atopic Dermatitis Market held 41% share and is expected to grow at a 9% CAGR through 2035. Strong veterinary infrastructure, access to innovative dermatology treatments, and widespread adoption of advanced therapies such as monoclonal antibodies are supporting regional market growth. Pet owners' increasing willingness to invest in specialized care and the prevalence of chronic dermatological conditions among dogs further strengthen North America's market leadership.

Key players operating in the Global Canine Atopic Dermatitis Market include AB Science, Boehringer Ingelheim, Ceva, Dechra Veterinary Products, Elanco Animal Health, Kindred Biosciences, Nextmune, Phibro Animal Health Corporation, Toray Industries, Vetoquinol, Virbac, and Zoetis. Companies in the Global Canine Atopic Dermatitis Market are focusing on R&D to develop innovative therapies, including monoclonal antibodies, targeted oral medications, and combination treatments. They are investing in clinical trials to demonstrate safety and efficacy while expanding product portfolios to address different severity levels and breeds. Strategic collaborations with veterinary clinics and distribution partners, along with educational initiatives to increase awareness among pet owners and veterinarians, are central to expanding market reach. Firms are also entering emerging markets and leveraging digital marketing to increase product adoption and improve brand visibility, enhancing their competitive position.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Route of administration trends
  • 2.2.4 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising pet ownership and humanization of pets
    • 3.2.1.2 Increased awareness of skin disorders and advanced treatment options
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effect of few medications
    • 3.2.2.2 Off-label use of human drugs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing demand and utilization of combination therapies
    • 3.2.3.2 Development of pediatric ulcerative colitis treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Pricing analysis (Driven by primary research)
• 3.6 Pipeline and clinical trials landscape
• 3.7 Future market trends
• 3.8 Impact of AI and generative AI on the market
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Glucocorticoids
• 5.3 Antihistamines
• 5.4 Immunosuppressants
• 5.5 MAbs
• 5.6 Other products

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Topical
• 6.4 Injectable

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Retail pharmacies
• 7.3 Veterinary hospital pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AB Science
• 9.2 Boehringer Ingelheim
• 9.3 Ceva
• 9.4 Dechra Veterinary Products
• 9.5 Elanco
• 9.6 Kindred Biosciences
• 9.7 Nextmune (Vimian)
• 9.8 Phibro Animal Health Corporation
• 9.9 Toray Industries
• 9.10 Vetoquinol
• 9.11 Virbac
• 9.12 Zoetis